Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.

Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

A user is considering a 3-in-1 capsule containing Finasteride, Minoxidil, and Biotin for hair loss. Concerns are raised about Biotin's impact on the effectiveness of Finasteride and Minoxidil, and the cost is unclear without logging in.

A 23-year-old male is using finasteride (1mg daily), derma rolling, and Nizoral for hair loss treatment, experiencing increased shedding and side effects like anxiety, decreased libido, and fatigue. Despite no positive changes in hair after three months, he plans to continue finasteride and may consider RU58841 or CB as future treatments, avoiding minoxidil due to past negative experiences.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Some users report minor hair regrowth using natural treatments like peppermint oil, dermarolling, and lifestyle changes, but results are limited. Others find more success with treatments like minoxidil, finasteride, and nizoral, while some remain skeptical of natural methods.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

A user shared their 3-month hair regrowth progress using finasteride, minoxidil, Redensyl, and a derma roller, along with vitamin and biotin supplements. They have seen significant improvement and regained confidence, despite initially losing hair due to seborrheic dermatitis and male pattern baldness.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

User Topher1999 achieved hair regrowth using Dutasteride 3 times a week and microneedling with Dr. Pen Ultima A6 every 2 weeks for 9 months. They believe microneedling is the main reason for hairline gains.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

A 3 year progress of using Finasteride, Minoxidil, and Derma Rolling for hair loss; it has resulted in considerable improvement.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Blocking DHT may slow down aging and improve skin, with users reporting positive effects from finasteride. Minoxidil and RU58841 are also mentioned as treatments.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

User taking 1mg finasteride daily for 2 years, wants to block more scalp DHT. Seeks reference for additional topical DHT blockers like alfatradiol and fluridil.

A 32-year-old female seeks ways to lower DHT without weight gain, experiencing issues with spiro and saw palmetto. Suggestions include topical finasteride, low-dose oral therapies, and checking various health markers.

Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.